XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Description of discount rate     in a revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%  
Weighted average discount rate operating lease 9.09%      
Increase In Right Of Use Asset And Liability $ 1,100,000      
Operating lease maturity years 8 years 9 months 29 days      
Research and development expenses $ 35,500,000      
Net Of Discount 11,800,000      
Vendor Obligations [Member]        
Estimated reaming cost of clinical study 600,000      
Landlord [Member]        
Additional Deposit Amount       $ 200,000
Incremental borrowing, derivative variable rate   8.45%    
Lease description   The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.    
Non current assets   $ 1,900,000    
Financing arrangement 11,100,000 2,400,000    
Payments Made By Landlord 2,400,000      
October 1, 2019 [Member] | Transaction Two [Member]        
Change in right of use of assets and liability   1,000,000.0    
Current balance 200,000 10,000    
Cash paid related to operating leases 30,000 300,000.0    
Net book value operating lease right of use assets 1,900,000 2,100,000    
Operating lease - liability 2,000,000.0 210,000    
Operating lease expense $ 400,000 $ 200,000    
October 1, 2019 [Member] | Transaction One [Member]        
Operating lease maturity years 6 years 29 days      
Weighted average discount rate   8.45%    
Change in right of use of assets and liability $ 16,500,000      
Current balance 1,600,000 $ 600,000    
Operating lease - liability 1,800,000 1,700,000    
Finance lease liability 13,500,000      
Net book value of the finance lease right of use asset 10,900,000 12,700,000    
Balance of the finance lease liability 13,300,000 13,800,000    
Cash paid related to finance leases 0 2,500,000    
Cash paid related to finance leases interest 1,200,000 1,200,000.0    
Ergomed [Member]        
Research and development expenses 500,000 1,600,000    
Net Of Discount 100,000 $ 600,000    
Clinical service trial 10,000,000      
Additional clinical trial $ 2,000,000